Can a simple supplement slow ALS? duke launches new trial
NCT ID NCT07589764
First seen May 17, 2026 · Last updated May 21, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a dietary supplement called HMB is safe and can slow the progression of ALS. About 100 adults with ALS will take HMB and be monitored for changes in function and blood markers. The goal is to see if HMB can lower certain proteins linked to nerve damage and help maintain daily abilities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Medical Center
Durham, North Carolina, 27705, United States
Contact
Contact Email: •••••@•••••
-
Temple University
Philadelphia, Pennsylvania, 19122, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.